Royalty Pharma Plc · NASDAQ:RPRX
Royalty Pharma — Merger or Acquisition (September 2025)
7 slides from Royalty Pharma's merger presentation, September 2025
Slide 1: Royalty Pharma
ROYALTY PHARMA
Slide 2: Obexelimab royalty acquisition
Obexelimab royalty acquisition September 2025
Slide 3: Forward Looking Statements
Forward Looking Statements This presentation has been prepared by Royalty Pharma plc (the “Company”), is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities. The information set forth herein does not purport to be complete or
Slide 4: Key messages
Key messages 1 2 3 Compelling opportunity in IgG4-RD: underappreciated, Structure yields attractive IgG4-RD for obexelimab high unmet need market returns B cells are a well validated target in IgG4-RD is a rare autoimmune disorder Funding scales as obexelimab progresses; Immunoglobulin G4-related di
Slide 5: Acquired royalty on obexelimab for IgG4-RD
Acquired royalty on obexelimab for IgG4-RD • Up to $300m in funding ▪ $75m upfront at close 5.5% royalty on worldwide ▪ $75m milestone upon achievement of defined success criteria in sales of obexelimab INDIGO Phase 3 trial in IgG4-RD ▪ $75m milestone upon FDA approval for IgG4-RD ▪ $75m milestone u
Slide 6: Obexelimab – addressing significant unmet need in IgG4-RD
Obexelimab – addressing significant unmet need in IgG4-RD Phase 2 proof-of-concept data (1) • Obexelimab is potentially the first non-depleting B cell modulating therapy in IgG4-RD 20 18 ▪ CD19 x FCγRIIb bifunctional mAb that dampens B cell Last scheduled IgG4-RD Responder Index Score 16 signaling w
Slide 7: Royalty Pharma sees blockbuster potential in IgG4-RD
Royalty Pharma sees blockbuster potential in IgG4-RD RP’s proprietary claims analytics drives conviction in IgG4-RD opportunity Limited Advanced Growing Prevalence High Steroid Burden Therapy Uptake >20,000 US patients ~40% of diagnosed patients ~30% of treated patients Confirmed by RP proprietary r
Royalty Pharma — Merger or Acquisition (September 2025) on 6ix